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Abstract
Introduction Of all malignant processes of the oral mucosa,
0.5% are malignant melanomas. Because of late diagnosis,
pattern of growth, close proximity to the bone (particularly
in palatinal localizations), and the correlated infiltration,
malignant melanomas have a bad prognosis.
Patients and methods In this retrospective study, six cases
of patients with oral mucosal malignant melanoma are
evaluated, and a critical review of the literature is presented.
The female to male proportion was 1:1 with an average age
of 60.2 years; all patients were treated between January
1999 and July 2007. A neck dissection was performed on
two patients because of clinically positive lymph nodes;
one patient received interleukin 2 therapy, and three
patients received postoperative radiotherapy. Two male
patients died.
Conclusions We recommend biopsy on every growing
lesion, pigmented or nonpigmented, for the required
diagnosis and, in cases of malignant melanoma, wide
excision as a second step. Neck dissections should be
performed in patients with clinically positive lymph nodes.
Concerning interleukin 2 therapy, further studies should be
performed in order to evaluate a routine application.
Keywords Malignant melanoma . Oral mucosa . Head and
neck oncology
Introduction
Melanoma of the mucosa is very rare, presenting in only
1.3% of all melanomas [1], and it is especially rare in
patients below the age of 30 years [2]. The peak age is
between 65 and 79 years [3]. No risk factors for intraoral
lesions have been clearly identified to date [4]. For mucosal
melanomas, distribution on the head and neck occurs in
55.4% of cases, followed by anal/rectal (23.8%), female
genital tract (18%), and urinary tract sites (2.8%) [1]. The
most frequently affected sites in the oral cavity are the
maxillary gingival and the palate [5, 6], and they are more
commonly affected in Japan and Africa than in Western
countries [2, 7, 8]. The development of oral malignant
melanomas (OMM) and the function of melanocytes in the
oral mucosa have still not been clearly identified. One
reason for the rare appearance of OMM might be the low
concentration of melanocytes in the oral mucosa. In single
tissue sections of the gingiva, the ratio is one melanocyte to
15 keratinocytes, whereas in the skin of the cheek, the ratio
is 1:4 and in the trunk 1:14 [5]. Melanocytes migrate much
less frequently to endodermally derived mucosa—e.g.,
nasopharynx, larynx, esophagus, or tracheobronchial tree;
A. L. D. Kruse :K. W. Graetz :H.-T. Luebbers (*)
Clinic for Craniomaxillofacial and Oral Surgery,
University Hospital Zurich,
Frauenklinikstr. 24,
8091 Zürich, Switzerland
e-mail: t.luebbers@gmail.com
M. O. Riener
Department of Pathology, University Hospital Zurich,
Zurich, Switzerland
Oral Maxillofac Surg (2010) 14:143–147
DOI 10.1007/s10006-010-0207-z
therefore, mucosal malignant melanomas are rare in these
locations [3]. Concerning the difference between oral
melanomas arising in the squamous or the respiratory
(sinonasal) mucosa, the clinical outcome is slightly, but not
significantly, worse in sinonasal melanomas. Prasad et al.
[9] studied the difference in clinical behavior of 36 oral
versus 59 sinonasal malignant melanoma. The latter
demonstrates more aggressive morphologic features, but
prognosis remains similar in both groups. It is striking,
however, that in the squamous mucosa men are affected 3.5
times more frequently than women [9].
Three criteria for the diagnosis of primary oral melano-
ma were proposed by Greene et al. [10]: (1) demonstration
of malignant melanoma in the oral mucosa, (2) presence of
“junctional activity” in the lesion, (3) and inability to show
malignant melanoma at another primary site. But junctional
activity is now seen as an unreliable indicator that the
lesion is primary because melanoma metastasis can also
involve the epithelium junction.
For determining the stage of cutaneous malignant
melanomas, Breslow’s depth of penetration and Clark’s
level of invasion, which correspond to the regional lymph
node status and presence/absence of metastasis, have been
used. Furthermore, two different growth patterns have been
mentioned: (1) a radial growth phase that tends not to
invade the underlying reticular corion but is associated with
metastasis and (2) the vertical growth pattern, invasive and
growing before metastasis can occur [3]. For mucosal
malignant melanomas, Clark’s level of invasion cannot be
applied because of missing histological landmarks like
papillary and reticular dermis [11]; in addition, oral
malignant mucosas have a radial growth phase [2] with
early metastasis.
Therefore, the purpose of this study was to determine the
initial symptoms, localization, stage, presence of regional or
distant metastases, and treatment.
Patients and methods
The records of all patients with mucosal malignant
melanoma from January 1999 to July 2007, six patients
(three females, three males) treated at the Clinic for
Craniomaxillofacial and Oral Surgery, University Hospital
Zurich, were systematically reviewed. Criteria for inclusion
were histologically proven primary malignant melanoma of
the oral cavity. Criteria for exclusion were inadequate
information, secondary oral malignant melanoma, and
recurrent disease. Data of site of tumor, histopathology,
stage, presence of regional or distant metastases, treatment,
recurrence, and outcome were analyzed.
All patients had incisional biopsy performed before
definitive treatment.
Results
Age, sex, and primary sites
Subjects involved were three female and three male patients
with an average age of 60.2 years. All patients revealed an
OMM of the maxilla. The initial clinical presentation is
listed in Table 1.
Initial symptoms, stages, and course of the disease
The primary symptoms were pigmentation in three cases
and painless swelling in three cases (Fig. 1). No bleeding
or pain as a first symptom was reported. In all patients, a
biopsy was first performed, and wide excision followed as
a second step. Two patients presented primary positive
lymph nodes, so a neck dissection was immediately
performed.
Histological findings
In two (with clinical T1 status) out of the four patients, the
primary incisional biopsy was taken alio loco and a clear
determination of infiltration depth was impossible, but in
one of the two patients a superficial spreading growth
pattern (patient 6 in Table 2) was observed. Concerning
the melanoma marker, HMB-45, S-100 protein, and
tyrosinase were used. One case was an amelanotic
melanoma.
The tumors consisted of highly atypical melano-
cytes with partial pigmentation. They showed focal
necrosis and infiltration of the gnathic bones (Fig. 2a,
Table 1 Initial clinical presentation
Gender Male 3
Female 3
Localization Lateral maxillary alveolus 4
Anterior maxilla 2
T status T1 2
T2 1
T3 0
T4 3
N status N0 5
N1 0
N2a 0
N2b 0
N2c 1
N3 0
Metastases M0 6
M1 0
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b). Three of the cases were composed of spindle cell
melanomas.
Treatment results
Two (male) patients out of six died because of the
malignant melanoma. After 3 months, one of these two
patients had developed lung metastases; he received
interleukin 2 therapy after metastasis, but he died. One
male patient had a recurrence.
Three of the six patients underwent directly postsurgical
radiation therapy. None of the patients received chemother-
apy (Table 2).
Discussion
Clinically, OMM can be divided into five types: (1)
pigmented nodular, (2) nonpigmented nodular, (3) pig-
mented macular, (4) pigmented mixed, and (5) nonpig-
mented mixed type [12]. Differential diagnosis include
drug-, disease-, pregnancy-, or smoking-associated mela-
nosis, oral melanotic maculae, Kaposi’s sarcoma, physio-
logic pigmentation, melanoacanthoma, and nevus.
Outcome
It is generally accepted that the outcomes for oral malignant
melanomas are worse than those for the cutaneous form.
About 10% of oral melanomas are amelanotic, and more
than 95% of the lesions are anti-S-100 antigen positive,
with more specific markers including HMB 45, Melan-A,
and antityrosinase [13]. These amelanotic malignant mela-
nomas have a worse prognosis than other kinds because of
the delays in establishing the correct diagnosis and also
because they are thought to be more aggressive than
pigmented melanomas [8]. One of the two patients that
died had an amelanotic malignant melanoma (patient 2 in
Table 2) and presented early lung metastases.
Rogers et al. [14] reported that 50% of all patients with
oral melanoma had regional lymph node metastases. In our
patients, one with OMM revealed directly positive lymph
nodes, so a neck dissection was performed. We did no
elective neck dissection on N0 tumors. Lens et al. [15] did a
meta-analysis of 1,522 cases and showed that there is no
Fig. 1 Painless swelling as a first symptom
Table 2 Initial staging, treatment, and outcome of the presented patients
Patient Sex cTNM Treatment Local recurrence Metastases Survival Follow-up time
(months)
1 m T4N0M0 Resection, RT – Skin metastases DOD 12
Recurrence (skin)
Involvement of skull base
2 m T3N2c0o Resection, bilat. neck
dissection, RT
Local recurrence
(17 months)
Ileum metastases DOD 9
Pulmonary and mesenterial
metastases
3 f T4N0M0 Resection, RT – – Alive,
tu-free
32
4 f T1N0M0 Resection – Metastases lower eyelid Alive,
tu-free
42
5 f T4N0M0 Resection – Pulmonary metastasis Palliative 26
6 m T1N0M0 Resection – Contralateral cervical lymph
node metastasis
Palliative 13
Cheek metastasis
Cervical lymph node
metastasis
Pulmonary, mediastinal, liver
metastases
DOD dead of disease
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significant overall survival benefit for patients undergoing
elective neck dissections.
There are different reasons for aggressive behavior in
oral malignant melanomas. One reason is, on the one hand,
the presence of the vertical more aggressive growth
(nodular) with invasion of the underlying submucosa and,
on the other hand, the radial growth (superficial spreading)
phase that is characterized by early metastasis [5]. In the
present study, one patient revealed a superficial spreading
growth pattern (patient 6 in Table 2) with primary T1 status
and early metastases. Furthermore, the diagnosis can be
delayed because most of the oral forms are painless in the
early stages and do not reveal ulceration like the oral
squamous cell carcinomas. In the present study, no patient
had ulceration, bleeding, or pain as a first symptom.
However, the overall 5-year survival rate is <30% [16–18].
Another important prognostic factor is the early metas-
tasis in oral malignant melanomas because, in certain
localizations like the palate, the tumor does not need to
invade very deeply before reaching the bone, and radiologic
evidence of bony erosions has been associated with early
hematogenous spread [2]. In our study population, all
patients had malignant melanomas in the upper jaw.
In the oral cavity, wide excisions are limited because of
the anatomical structures; therefore, surgical results cannot
always be compared between cutaneous and oral forms.
The average age of patients with OMM in our study
population was 60.2 years of age; the age is, in general,
higher in comparison to squamous cell carcinomas. The
highest incidence in the group is between 40 and 70 years
as reported [13, 19]. Therefore, the higher age also plays an
important role in the outcome.
Bad prognostic factors, in general, correlate with tumor
thickness and ulceration. Several studies also showed that
male patients had a worse prognosis; the two patients that died
and the one patient with a recurrence were men. In general,
malignant melanomas are found almost three times more
frequently in men than in women, though in the present
retrospective study the male–female distribution was 1:1.
Gingival melanoma has a slightly greater 5-year survival
rate than that for palatinal melanoma, with a longer median
survival period (46 vs. 22 months). Nodal involvement with
oral melanoma reduces median survival substantially from
46 months to only 18 months [5]. In the literature, different
survival times are mentioned for OMM. Chang et al. [1]
reported a 5-year disease-specific survival for OMM of 31.7%.
Meleti et al. [7] reported a 5-year survival of only 15%.
To sum up, the factors that are significant in lower
disease-specific survival rates are primary high clinical
stage, tumor thickness greater than 5 mm, presence of
vascular invasion, absence of melanosis, and development
of lymph node or distant metastases.
Excisional versus incisional biopsy
Cytological tests on brushed samples seem not to be
reliable [4] and are, like fine-needle aspiration, contra-
indicated [3]. Concerning biopsies in malignant melano-
mas, dissemination of malignant cells in the tissue, blood,
or lymphatic stream is discussed. Bong et al. [20], in a
retrospective study of 265 patients having an incisional
biopsy of cutaneous melanoma and 496 control cases of
excisional biopsy, reported no correlation of malignant
spreading; and Lederman et al. [21] reported similar results.
One patient had been lasered before because of pigmen-
tation. We recommend that any growing lesion, pigmented
or nonpigmented, should be biopsied without delay for a
diagnosis.
Treatment
Most authors advocate wide local excision of the tumor [4,
22]. Oral malignant melanomas are not very radiosensitive,
but postoperative radiotherapy is generally recommended in
Fig. 2 a Melanoma infiltrating the maxillary bone (arrow), H&E, ×100. b Melanoma cells positive for HMB-45 (clone HMB-45, 1:50,
DAKO, ×200)
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multiple positive nodes, in extranodal spread, and in poor
prognostic pathologic features [7, 23].
The goal of immunotherapy is an activation of immune-
competent cells in the tumor defense when, for example,
interferon or interleukin are administered [24]. Verma et al.
[25] were able to show in a review that a high dose of
interferon is associated with a significant improvement in
disease-free survival and a reduction of 2-year mortality.
Concerning interleukin 2 therapy, between 1985 and
2006, Petrella et al. [26] reviewed noncomparative phase II
trials of high-dose, single-agent interleukin 2 with a
response rate of 10–33% and with a complete response
rate from 0% to 15%. The one patient that was treated with
interleukin 2 in the present study already had lung
metastasis and died. There is still a need for further
investigations concerning immunotherapy in this particular
group of malignancies.
Conclusion
Every growing lesion, pigmented or nonpigmented,
requires a diagnosis; therefore, we recommend biopsy
and, because of anatomical limits, wide excision as a
second step. In cases of clinically positive lymph nodes,
a neck dissection should be done immediately. In
patients with negative lymph nodes, an elective neck
dissection should not be offered directly. Despite the
improvement of surgical techniques and the introduction
of new chemotherapeutic agents, prognosis of this
malignancy remains poor.
Competing interests The authors declare that they have no
competing interests.
References
1. Chang AE, Karnell LH, Menck HR (1998) The National Cancer
Data Base report on cutaneous and noncutaneous melanoma: a
summary of 84, 836 cases from the past decade. The American
College of Surgeons Commission on Cancer and the American
Cancer Society. Cancer 83(8):1664–1678
2. Rapini RP et al (1985) Primary malignant melanoma of the oral
cavity. A review of 177 cases. Cancer 55(7):1543–1551
3. Femiano F et al (2008) Oral malignant melanoma: a review of the
literature. J Oral Pathol Med 37(7):383–388
4. Garzino-Demo P et al (2004) Oral mucosal melanoma: a series of
case reports. J Craniomaxillofac Surg 32(4):251–257
5. Hicks MJ, Flaitz CM (2000) Oral mucosal melanoma: epidemi-
ology and pathobiology. Oral Oncol 36(2):152–169
6. Gu GM, Epstein JB, Morton TH Jr (2003) Intraoral melanoma:
long-term follow-up and implication for dental clinicians. A case
report and literature review. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 96(4):404–413
7. Meleti M et al (2007) Oral malignant melanoma: a review of the
literature. Oral Oncol 43(2):116–121
8. Notani K et al (2002) Amelanotic malignant melanomas of the
oral mucosa. Br J Oral Maxillofac Surg 40(3):195–200
9. Prasad ML et al (2003) Clinicopathologic differences in malignant
melanoma arising in oral squamous and sinonasal respiratory
mucosa of the upper aerodigestive tract. Arch Pathol Lab Med 127
(8):997–1002
10. Greene GW et al (1953) Primary malignant melanoma of the oral
mucosa. Oral Surg Oral Med Oral Pathol 6(12):1435–1443
11. Prasad ML et al (2004) Primary mucosal melanoma of the head
and neck: a proposal for microstaging localized, stage I (lymph
node-negative) tumors. Cancer 100(8):1657–1664
12. Tanaka N et al (2004) Primary malignant melanoma of the oral
cavity: assessment of outcome from the clinical records of 35
patients. Int J Oral Maxillofac Surg 33(8):761–765
13. Rapini RP (1997) Oral melanoma: diagnosis and treatment. Semin
Cutan Med Surg 16(4):320–322
14. Rogers RS 3rd, Gibson LE (1997) Mucosal, genital, and unusual
clinical variants of melanoma. Mayo Clin Proc 72(4):362–366
15. Lens MB, Nathan P, Bataille V (2007) Excision margins for
primary cutaneous melanoma: updated pooled analysis of ran-
domized controlled trials. Arch Surg 142(9):885–891, discussion
891–893
16. Thompson LD, Wieneke JA, Miettinen M (2003) Sinonasal tract
and nasopharyngeal melanomas: a clinicopathologic study of 115
cases with a proposed staging system. Am J Surg Pathol 27
(5):594–611
17. Yii NW et al (2003) Mucosal malignant melanoma of the head and
neck: the Marsden experience over half a century. Clin Oncol (R
Coll Radiol) 15(4):199–204
18. Patel SG et al (2002) Primary mucosal malignant melanoma of the
head and neck. Head Neck 24(3):247–257
19. Gorsky M, Epstein JB (1998) Melanoma arising from the mucosal
surfaces of the head and neck. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod 86(6):715–719
20. Bong JL, Herd RM, Hunter JA (2002) Incisional biopsy and
melanoma prognosis. J Am Acad Dermatol 46(5):690–694
21. Lederman JS, Sober AJ (1985) Does biopsy type influence
survival in clinical stage I cutaneous melanoma? J Am Acad
Dermatol 13(6):983–987
22. Mendenhall WM et al (2005) Head and neck mucosal melanoma.
Am J Clin Oncol 28(6):626–630
23. Barker BF et al (1997) Oral mucosal melanomas: the WESTOP
Banff workshop proceedings. Western Society of Teachers of Oral
Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83
(6):672–679
24. Mohr P, Weichenthal M, Hauschild A (2003) Adjuvant therapy in
melanoma. Onkologie 26(3):227–233
25. Verma S et al (2006) Systematic review of systemic adjuvant
therapy for patients at high risk for recurrent melanoma. Cancer
106(7):1431–1442
26. Petrella T et al (2007) Single-agent interleukin-2 in the treatment
of metastatic melanoma: a systematic review. Cancer Treat Rev 33
(5):484–496
Oral Maxillofac Surg (2010) 14:143–147 147
